Adipokines as a novel link between obesity and atherosclerosis.

The traditional perception of adipose tissue as a storage organ of fatty acids has been replaced by the notion that adipose tissue is an active endocrine organ, releasing various adipokines that are involved in the pathogenesis of obesity-related metabolic disturbances. Obesity is a well-known risk factor for atherosclerosis, and accelerates atherosclerosis by many mechanisms such as increase in blood pressure and glucose level, abnormal lipid profiles, and systemic inflammation. Furthermore, growing evidence suggests that some adipokines directly mediate the process of atherosclerosis by influencing the function of endothelial cells, arterial smooth muscle cells, and macrophages in vessel walls. In obese patients, the secretion and coordination of such adipokines is abnormal, and the secretion of specific adipokines increases or decreases. Accordingly, the discovery of new adipokines and elucidation of their functions might lead to a new treatment strategy for metabolic disorders related to obesity, including cardiovascular diseases.

[1]  S. Bonner-Weir,et al.  Improved Glucose and Lipid Metabolism in Genetically Obese Mice Lacking aP2. , 2000, Endocrinology.

[2]  S. Kihara,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[3]  K. Toyoshima,et al.  Human Intelectin Is a Novel Soluble Lectin That Recognizes Galactofuranose in Carbohydrate Chains of Bacterial Cell Wall* , 2001, The Journal of Biological Chemistry.

[4]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[5]  W. Garvey,et al.  The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. , 2002, Atherosclerosis.

[6]  Philippe Froguel,et al.  Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.

[7]  L. Makowski,et al.  Fatty acid binding proteins--the evolutionary crossroads of inflammatory and metabolic responses. , 2004, The Journal of nutrition.

[8]  Jeffrey B. Boord,et al.  Combined Adipocyte-Macrophage Fatty Acid–Binding Protein Deficiency Improves Metabolism, Atherosclerosis, and Survival in Apolipoprotein E–Deficient Mice , 2004, Circulation.

[9]  Y. Matsuzawa.  Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. , 2005, Atherosclerosis. Supplements.

[10]  Anand Rohatgi,et al.  Resistin Is an Inflammatory Marker of Atherosclerosis in Humans , 2005, Circulation.

[11]  A. Shuldiner,et al.  Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. , 2006, American journal of physiology. Endocrinology and metabolism.

[12]  S. Tam,et al.  Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. , 2006, Clinical chemistry.

[13]  P. Zimmet,et al.  Chemerin is a novel adipokine associated with obesity and metabolic syndrome. , 2007, Endocrinology.

[14]  R. Parker,et al.  Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 , 2007, Nature.

[15]  A. Shuldiner,et al.  Omentin Plasma Levels and Gene Expression Are Decreased in Obesity , 2007, Diabetes.

[16]  E. Rimm,et al.  Plasma resistin levels and risk of myocardial infarction and ischemic stroke. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  H. Randeva,et al.  Omentin-1, a Novel Adipokine, Is Decreased in Overweight Insulin Resistant Women with the Polycystic Ovary Syndrome: Ex Vivo and in Vivo Regulation of Omentin-1 by Insulin and Glucose , 2022 .

[18]  K. Piestrzeniewicz,et al.  Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. , 2008, Metabolism: clinical and experimental.

[19]  O. Franco,et al.  Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. , 2008, European journal of endocrinology.

[20]  K. Sung,et al.  The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. , 2008, European journal of endocrinology.

[21]  P. Arner,et al.  Chemerin Is a Novel Adipocyte-Derived Factor Inducing Insulin Resistance in Primary Human Skeletal Muscle Cells , 2009, Diabetes.

[22]  S. Gay,et al.  The role of resistin as a regulator of inflammation: Implications for various human pathologies. , 2009, Clinical immunology.

[23]  L. Ho,et al.  Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. , 2009, Life sciences.

[24]  B. Göke,et al.  Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat Diet , 2010, Diabetes.

[25]  S. Kusachi,et al.  Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. , 2010, Atherosclerosis.

[26]  H. Randeva,et al.  Metformin Treatment May Increase Omentin-1 Levels in Women With Polycystic Ovary Syndrome , 2010, Diabetes.

[27]  H. Randeva,et al.  Identification of Chemerin Receptor (ChemR23) in Human Endothelial Cells: , 2009 .

[28]  S. Parlee,et al.  Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. , 2010, Endocrinology.

[29]  K. Clément,et al.  Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. , 2010, The Journal of clinical endocrinology and metabolism.

[30]  S. Kihara,et al.  Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men , 2011, Hypertension Research.

[31]  N. Hamdy,et al.  Serum omentin‐1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[32]  S. Tang,et al.  Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. , 2011, Cardiovascular research.

[33]  M. Okada,et al.  Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. , 2011, Biochemical and biophysical research communications.

[34]  H. J. Yoo,et al.  Circulating chemerin level is independently correlated with arterial stiffness. , 2012, Journal of atherosclerosis and thrombosis.